BioXcel TherapeuticsBTAI
Market Cap: $23.9M
About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Employees: 74
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
1% less funds holding
Funds holding: 74 [Q1] → 73 (-1) [Q2]
2.1% less ownership
Funds ownership: 28.14% [Q1] → 26.04% (-2.1%) [Q2]
53% less capital invested
Capital invested by funds: $26.7M [Q1] → $12.5M (-$14.2M) [Q2]
54% less call options, than puts
Call options by funds: $159K | Put options by funds: $346K
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 45% 1-year accuracy 118 / 261 met price target | 1,096%upside $7 | Buy Reiterated | 6 Sept 2024 |
Canaccord Genuity Sumant Kulkarni 52% 1-year accuracy 12 / 23 met price target | 1,096%upside $7 | Buy Maintained | 30 Aug 2024 |
UBS Colin Bristow 27% 1-year accuracy 4 / 15 met price target | 71%upside $1 | Neutral Maintained | 9 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 45% 1-year accuracy 118 / 261 met price target | 1,096%upside $7 | Buy Maintained | 8 Aug 2024 |
Canaccord Genuity Sumant Kulkarni 52% 1-year accuracy 12 / 23 met price target | 1,096%upside $7 | Buy Maintained | 27 Jun 2024 |
Financial journalist opinion
Based on 3 articles about BTAI published over the past 30 days